Salsalate shows efficacy as add-on treatment in diabetes

07/2/2013 | InternalMedicineNews.com (free registration)

Research on patients with poorly controlled type 2 diabetes revealed those who used oral salsalate as an add-on to one to three diabetes drugs attained lower A1C rates at 48 weeks than those in the placebo group. Data also showed 41% of those in the salsalate group attained 0.5 percentage points or greater reductions in A1C at the study's conclusion, compared with 23% of those who took a placebo. The findings appear in the Annals of Internal Medicine.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC